BIvideocpd6

Name:

Surname:

MP Number:

Email address:

Contact number:

Question 1
True or false: Patients with AF will benefit from dabigatran whether or not they have a prior history of coronary artery disease (CAD)/myocardial infarction (MI)

a) True

b) False

Question 2
What do the p-values for interaction imply for dabigatran in patients with/without prior CAD/MI?

a) 150 mg is more effective in patients without prior CAD/MI

b) 110 mg is more effective in patients with prior CAD/MI

c) 150 mg is more effective in patients with prior CAD/MI

d) Safety and efficacy outcomes are consistent between the two doses

Question 3
Choose the correct answer. Symptomatic heart failure:

a) Patients are prone to arrhythmias

b) Causes fatigue and peripheral oedema

c) Is a debilitating disease

d) All of the above

Question 4
The benefits of dabigatran vs. warfarin were maintained in patients with symptomatic heart failure for which of the following events?

a) Stroke/SE

b) Hospitalisations

c) Intracranial haemorrhage

d) All of the above

Question 5
What is the major concern when anticoagulating patients with a history of prior stroke?

a) Haemorrhagic stroke

b) Gastrointestinal bleeding

c) All-cause death

d) All of the above

Question 6
True or false: Dabigatran increases the risk of intracranial haemorrhage vs. warfarin in patients with a history of prior stroke.

a) True

b) False

Question 7
The efficacy and safety of dabigatran 110 mg and 150 mg is not influenced by the presence of:

a) Valvular heart disease

b) Stroke

c) Cardiovascular disease

d) All of the above